Trial launched to evaluate neuroendocrine tumour vaccine
A Phase II trial evaluating a treatment for metastatic neuroendocrine tumours (NETs) has been launched.
SurVaxM, a peptide vaccine, has been developed by biotechnology company MimiVax and will be evaluated in a study conducted at Rosewell Park, New York.
The trial will evaluate SurVaxM in combination with temozolomide in patients with progressing neuroendocrine tumours, comparing the safety and effect of temozolomide combined with SurVaxM to temozolomide alone in patients with metastatic NETs that are progressing.
SurVaxM has previously shown it can produce an immune system response against cancer cells that express the protein survivin and may block the growth of new tumour cells. The new clinical trial builds on Phase I findings, which proved SurVaxM was well tolerated in NET patients and demonstrated measurable clinical benefit with elevated antibody responses.
“This Phase II trial is the result of years of careful, collaborative science between MimiVax, Roswell Park Comprehensive Cancer Center, and the neuroendocrine tumour community,” said Michael Ciesielski, CEO and Co-founder of MimiVax.
“NET patients deserve more options, and we are excited to see if SurVaxM can become a new treatment for them.”
Neuroendocrine tumours are a rare type of cancer that arise from hormone-producing cells throughout the body, most commonly in the gastrointestinal tract and lungs. The number of reported cases has increased significantly over the past two decades, with an estimated 28,000 people diagnosed in the US each year.
“Patients need more options to treat NETs, and the Phase I data gave us confidence this is a safe, immunologically active approach to try in a larger patient population,” added Jasmeet Kaur, Assistant Professor at Roswell Park and Principal Investigator on the trial.
“We are excited to see if the next trial confirms a meaningful clinical benefit that advances patient care.”
